Literature DB >> 8586105

Positive thyroid cancer scintigraphy using technetium-99m methoxyisobutylisonitrile.

J Nĕmec1, O Nývltová, T Blazek, P Vlcek, P Racek, Z Novák, M Preiningerová, M Hubácková, M Krízo, J Zimák, R Bílek.   

Abstract

The aim of the study was to evaluate the possibility of detecting thyroid cancer recurrences without the need for withdrawal of thyroid suppressive treatment. Upper-body or whole-body scintigraphy was performed in a group of 200 patients evaluated for differentiated thyroid cancers in 1993 and 1994 using technetium-99m sestamibi. Scans were performed 20-30min following i.v. administration of 500MBq of 99mTc-methoxyisobutylisonitrile (MIBI). Bone and lung metastases were detected with very high sensitivity and specificity, with a very high predictive value of negative results and a somewhat lower predictive value of positive results. The sensitivity and specificity of findings in the neck were lower but the predictive value of negative results was high. Whole-body scans with 99mTc-MIBI are a useful tool in the follow-up of patients with differentiated thyroid cancer, for the detection of distant metastatic lesions.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8586105     DOI: 10.1007/bf01736992

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  7 in total

1.  [A comparison of 201Tl and 99mTc-MIBI in the follow-up of differentiated thyroid carcinomas].

Authors:  B Briele; A Hotze; J Kropp; A Bockisch; B Overbeck; F Grünwald; W Kaiser; H J Biersack
Journal:  Nuklearmedizin       Date:  1991-08       Impact factor: 1.379

2.  Effective visualization of suppressed thyroid tissue by means of baseline 99mTc-methoxy isobutyl isonitrile in comparison with 99mTc-pertechnetate scintigraphy after TSH stimulation.

Authors:  A Vattimo; P Bertelli; L Burroni
Journal:  J Nucl Biol Med       Date:  1992 Oct-Dec

3.  The role of technetium-99m sestamibi whole-body scans in diagnosing metastatic Hürthle cell carcinoma of the thyroid gland after total thyroidectomy: a comparison with iodine-131 and thallium-201 whole-body scans.

Authors:  T C Yen; H D Lin; C H Lee; S L Chang; S H Yeh
Journal:  Eur J Nucl Med       Date:  1994-09

4.  Role of technetium-99m sestamibi in localisation of thyroid cancer metastases.

Authors:  F X Sundram; A S Goh; E S Ang
Journal:  Ann Acad Med Singapore       Date:  1993-07       Impact factor: 2.473

5.  Comparison of the distribution of diagnostic and thyroablative I-131 in the evaluation of differentiated thyroid cancers.

Authors:  J Nĕmec; S Röhling; V Zamrazil; D Pohunková
Journal:  J Nucl Med       Date:  1979-02       Impact factor: 10.057

6.  Quick diagnosis of hyperthyroidism with semiquantitative 30-minute technetium-99m-methoxy-isobutyl-isonitrile thyroid uptake.

Authors:  C H Kao; S J Wang; S Q Liao; W Y Lin; C Y Hsu
Journal:  J Nucl Med       Date:  1993-01       Impact factor: 10.057

7.  Positive thyroid cancer scintigraphy using 99Tcm-tetrofosmin (Myoview): a preliminary report.

Authors:  J Nĕmec; O Nývltová; M Preiningerová; P Vlcek; P Racek; Z Novák; T Blazek; J Zimák
Journal:  Nucl Med Commun       Date:  1995-08       Impact factor: 1.690

  7 in total
  4 in total

1.  Indium-111 octreotide scintigraphy for the detection of non-functioning metastases from differentiated thyroid cancer: diagnostic and prognostic value.

Authors:  Marcel P M Stokkel; Robbert B Verkooijen; Jan W A Smit
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02-26       Impact factor: 9.236

2.  Use of 99mTc-sestamibi SPECT/CT when conventional imaging studies are negative for localizing suspected recurrence in differentiated thyroid cancer: a method and a lesson for clinical management.

Authors:  Di Wu; Dorina Ylli; Cristiane J Gomes Lima; Wen Lee; Kenneth D Burman; Leonard Wartofsky; Douglas Van Nostrand
Journal:  Endocrine       Date:  2018-05-24       Impact factor: 3.633

3.  Visualisation of a paraganglioma by technetium-99m-sestamibi scintigraphy.

Authors:  M Piga; G P Farina; G L Loi; A Serra; M A Calia; L Lai; G Zucca; S Mariotti
Journal:  J Endocrinol Invest       Date:  1999-04       Impact factor: 4.256

4.  Indium-111-Octreotide scintigraphy in differentiated thyroid carcinoma metastases that do not respond to treatment with high-dose I-131.

Authors:  Marcel P M Stokkel; Henna I E Reigman; Robbert B T Verkooijen; Jan W Smit
Journal:  J Cancer Res Clin Oncol       Date:  2003-05-15       Impact factor: 4.553

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.